Zobrazeno 1 - 4 of 4 pro vyhledávání: '"Carl Zainaldin"'
3
Survival outcomes of patients with relapsed or refractory acute myeloid leukemia after venetoclax combined with hypomethylating agents
Autor: Carl Zainaldin, Sankalp Arora, Sri Bathini, Vishruti Pandya, Sejong Bae, Udita Gupta, Sarah Worth`, Kimo Bachiashvili, Ravi Bhatia, Kelly Nicole Godby, Omer Jamy, Sravanti Rangaraju, Barry Diamond, Josh D Oliver, Donna E. Salzman, Antonio Di Stasi, Pankit Vachhani
Publikováno v: Journal of Clinical Oncology. 40:e18808-e18808
e18808 Background: Venetoclax in combination with hypomethylating agents (HMA+Ven) is the standard-of-care treatment for patients with newly diagnosed acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy. HMA+Ven is also commonl
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ab6395a9e4a4810214b1c29c08eb1012
https://doi.org/10.1200/jco.2022.40.16_suppl.e18808
Zobrazit plný text záznamu
4
Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemia
Autor: Sankalp Arora, Carl Zainaldin, Srilakshmi Bathini, Udita Gupta, Sarah Worth, Kimo Bachiashvili, Ravi Bhatia, Kelly Godby, Omer Jamy, Sravanti Rangaraju, Barry Diamond, Josh D. Oliver, Donna Salzman, Antonio Di Stasi, Pankit Vachhani
Publikováno v: Leukemia Research. 117:106844
Venetoclax (Ven) in combination with azacitidine or decitabine (hypomethylating agent; HMA) is the standard-of-care treatment for older (≥75 years) or intensive chemotherapy ineligible adults with newly diagnosed acute myeloid leukemia (AML). Tumor
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4947da4772e6780818e041e6aab874ff
https://doi.org/10.1016/j.leukres.2022.106844
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje